Physician profile
Robert Edwin Exten
NPI 1205832375
$210.97
in general payments reported to CMS, 2019-2025
11 companies · $30.98 in 2025
The $30.98 reported for 2025 was less than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.66 · 2021: $13.86 · 2023: $119 · 2024: $29.03 · 2025: $30.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $179.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $38.72 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $21.21 | 2023 | Lynparza, Keytruda |
| Regeneron Healthcare Solutions, INC. | $20.21 | 2023 | Libtayo |
| Pharmaessentia USA Corporation | $19.55 | 2023 | Besremi |
| Mirati Therapeutics, INC. | $18.48 | 2023 | Krazati |
| Exelixis INC. | $17.66 | 2019 | |
| Legend Biotech USA INC. | $17.23 | 2025 | Carvykti |
| Celgene Corporation | $15.13 | 2023 | Opdualag |
| Jazz Pharmaceuticals INC. | $14.52 | 2024 | |
| Incyte Corporation | $14.51 | 2024 | Pemazyre, Monjuvi |
| Caris Mpi, INC. | $13.75 | 2025 | Mi Cancer Seek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Exten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.